Search

everythinglearnresearchcommunity

for

Search:↓

Using tazarotene with GliSODin improves facial skin more than tazarotene alone.

Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.

Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.

Glibenclamide slows breast cancer cell growth by stopping cell division.

GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.

The effect of GLP-1 RAs on erectile function is unclear and needs more research.

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Pranlukast and mirabegron may work as new diabetes drugs.

Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

More research is needed to understand if GLP-1 agonists affect hair health.

Newer GLP-1 drugs like semaglutide may cause hair loss.

GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.

GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.

GLP-1 receptor agonists may help or harm hair health, needing more research.

GLP-1 agonists may increase the risk of hair loss.